Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...
Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...
Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...
The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...
Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...
DRIVING under the influence of drink or drugs, including prescription drugs, is usually to blame for cases of dangerous ...
SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...
Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those withou ...
ITI-1284 is under clinical development by Intra-Cellular Therapies and currently in Phase II for Generalized Anxiety Disorder (GAD).